---
business_slug: processor
capital_bounds_bbd:
  min: 300000
  max: 1000000
financial_method:
  horizon_years: 5
  discount_rate_pct: 15
  metrics: [IRR, NPV, ROI]
assumptions_version: 1.0
updated_at: 2025-09-09
---

# **Brief 2: Processor (Pharma-Grade Papain Refining, Barbados)**

**Value Proposition**

* Produce ≥6,000 USP U/mg papain powder, sterile and GMP-certified.  
* Offer Caribbean-based, Western-regulated quality alternative to Asian suppliers.  
* Enable pharma & cosmetic buyers to source closer to Western markets.

**Customer Segments**

* Pharmaceutical ingredient distributors (Merck, Mitsubishi, Sigma).  
* Wound care, nutraceutical, cosmetics companies.

**Key Activities**

* Purification: ultrafiltration, chromatography, lyophilisation.  
* Quality & regulatory compliance (GMP, HACCP, CoA).  
* Packaging and sterile handling.

**Key Resources**

* 25+ ha high-latex orchards (or secure crude supply).  
* GMP-compliant facility (≈US $1.5–2M CAPEX).  
* Skilled technicians & QA lab.

**Channels**

* Direct to pharma distributors.  
* Partnerships with global traders.  
* Export agents.

**Revenue Streams**

* Pharma-grade papain (US $60–90/kg).  
* Custom grades (sterile, high-activity).

**Cost Structure**

* High CAPEX amortisation.  
* Utilities, skilled labour, QC.  
* Regulatory audits.

**Critical Risks**

* Scale mismatch (10 ha too small; ≥16 ha baseline).  
* High fixed costs vs fluctuating demand.  
* Regulatory hurdles (FDA, EMA).
